Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar 4:9:53-64.
doi: 10.2147/IJGM.S88552. eCollection 2016.

Animal models of myasthenia gravis: utility and limitations

Renato Mantegazza  1 , Chiara Cordiglieri  1 , Alessandra Consonni  1 , Fulvio Baggi  1
Affiliations
Review

Animal models of myasthenia gravis: utility and limitations

Renato Mantegazza et al. Int J Gen Med. .

Abstract

Myasthenia gravis (MG) is a chronic autoimmune disease caused by the immune attack of the neuromuscular junction. Antibodies directed against the acetylcholine receptor (AChR) induce receptor degradation, complement cascade activation, and postsynaptic membrane destruction, resulting in functional reduction in AChR availability. Besides anti-AChR antibodies, other autoantibodies are known to play pathogenic roles in MG. The experimental autoimmune MG (EAMG) models have been of great help over the years in understanding the pathophysiological role of specific autoantibodies and T helper lymphocytes and in suggesting new therapies for prevention and modulation of the ongoing disease. EAMG can be induced in mice and rats of susceptible strains that show clinical symptoms mimicking the human disease. EAMG models are helpful for studying both the muscle and the immune compartments to evaluate new treatment perspectives. In this review, we concentrate on recent findings on EAMG models, focusing on their utility and limitations.

Keywords: AChR; autoimmunity; myasthenia gravis; neuroimmunology.

PubMed Disclaimer

References

    1. Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26:1054–1059. - PubMed
    1. Trotter JL, Ringel SP, Cook JD, et al. Morphologic and immunologic studies in experimental autoimmune myasthenia gravis and myasthenia gravis. Neurology. 1977;27:1120–1124. - PubMed
    1. Meriggioli MN. Myasthenia gravis with anti-acetylcholine receptor antibodies. Front Neurol Neurosci. 2009;26:94–108. - PubMed
    1. Tzartos SJ, Morel E, Efthimiadis A, et al. Fine antigenic specificities of antibodies in sera from patients with D-penicillamine-induced myasthenia gravis. Clin Exp Immunol. 1988;74:80–86. - PMC - PubMed
    1. Newsom-Davis J, Willcox N, Calder L. Thymus cells in myasthenia gravis selectively enhance production of anti-acetylcholine-receptor antibody by autologous blood lymphocytes. N Engl J Med. 1981;305:1313–1318. - PubMed